Rare Hemophilia Factors Market
Rare Hemophilia Factors Market Size, Share, Forecast, Growth Analysis, By Type (Factor I, Factor II, Factor V, Factor VII, Factor X, Factor XI, Factor XIII), By Application (Fresh Frozen Plasma, Factor Concentrates, Cryoprecipitate) & Region - Global Market Insights 2022 to 2032
Analysis of Rare Hemophilia Factors market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Rare Hemophilia Factors Market Outlook (2022-2032)
Expanding at a CAGR of 6%, the global rare hemophilia factors market is slated to increase from a valuation of US$ 290 million in 2022 to US$ 520 million by the end of 2032. The use of fresh frozen plasma is forecasted to increase at a CAGR of 6.2% through 2032. Fresh frozen plasma is widely utilized to treat bleeding episodes in rare hemophilia deficits due to the restricted availability of factor concentrates.
Hemophilia is a rare, acquired condition in which there are insufficient clotting factors, which prevent the blood from clotting. A protein called clotting factor is necessary for blood coagulation to generally occur. These proteins help the blood clot by interacting with platelets, which are tiny blood cell fragments that form in the bone marrow.
As the prevalence of numerous blood-related ailments such as myeloma, anemia, sickle cell anemia, and leukemia has increased, hematologists are paying closer attention to various discovery processes. Hematologists favor more effective treatment methods over exact diagnostic techniques.
One of the main factors propelling market expansion is the rising hemophilia prevalence, which contributes to the growing demand for treatment choices. Patients with severe hemophilia require ongoing treatment to keep their bloodstreams sufficiently stocked with clotting factors to stop bleeding.
Furthermore, patients who receive the right care are anticipated to experience a lower risk of major bleeding and to develop fewer co-morbid disorders. As a result, the number of patients with hemophilia is continuously surging, which has greatly boosted the demand for treatment, which will eventually rise product adoption rates.
Since hemophilia is a genetic ailment, there isn't a long-term treatment available. However, people replenish the missing factor proteins required for starting blood clotting using a variety of hemophilia treatment methods. The quality of life for persons with hemophilia is greatly enhanced by the use of medicines, including replacement therapy and hemophilia gene therapy.
The development of new treatment approaches in the global hemophilia market is anticipated to be fueled by significant research and development in the field of biotechnology for clotting factors, increasing campaigns and supportive government initiatives for raising awareness about Hemophilia drugs, and more. The goal of pharmaceutical corporations' efforts to increase access to medicines, diagnosis, and awareness around the world is to create public-private partnerships.
The industry is seeing a surge in the creation of novel factor concentrates as a result of rising R&D activity by significant market participants. Regulatory agencies have recently approved the marketing of numerous concentrations. The introduction of new products will probably grow the market. A wider range of new concentrates' accessibility can aid in raising patient awareness and offering them more therapeutic options.
Government regulations and initiatives have also raised patient and professional awareness of the rare hemophilia coagulation disorders, which has boosted the rate of this condition's diagnosis and treatment. With the approval of orphan drugs, better treatment options are now available for individuals with rare hemophilia disorders and other uncommon diseases whose needs have not yet been satisfied.
Patients are increasingly utilizing preventive therapies, which is helping the market expand. Prophylaxis has many benefits, including a decreased risk of joint injury and joint pain. Prophylactic treatment is advised for patients with severe, uncommon hemophilia disorders to stop bleeding.
The effectiveness and performance of prophylaxis are enhanced by ongoing treatment, which accelerates its adoption. This is likely to further accelerate market expansion over the coming years.
Report Attributes |
Details |
|---|---|
|
Rare Hemophilia Factors Market Size (2022) |
US$ 290 Million |
|
Projected Market Value (2032) |
US$ 520 Million |
|
Global Market Growth Rate (2022-2032) |
6% CAGR |
|
Market Share of Fresh Frozen Plasma |
40% |
|
Share in Hemophilia Market (2022) |
4% |
|
Key Companies Profiled |
|
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
What’s Driving Demand for Rare Hemophilia Factors?
“Advances in Treatment of Hemophilia & Approval of Innovative Techniques”
The approval of innovative treatment methods is one of the main factors fueling the growth of the global market for rare hemophilia factors. Individuals with hemophilia have a variety of effective and secure therapy options at their disposal, including cutting-edge extended half-life therapies that can get beyond the restrictions of the current prophylactic, especially in patients with hemophilia B.
Hemophilia types A and B are the most often occurring. The majority of treatment for hemophilic patients has been replacement therapy, which supplies the missing coagulation factors in hemophilia A and hemophilia B. Several market participants are concentrating on developing cutting-edge hemophilia treatment methods.
Key elements driving the expansion of the global hemophilia therapeutics market include the rising development of novel coagulating factors, improvements in healthcare facilities and infrastructure, particularly in developing and emerging nations, and an increase in disposable incomes that encourage people to spend more on better healthcare. In addition to this, the increasing acceptance of medical tourism in some countries would further fuel market expansion.
How is Industry Growth Being Restrained to Some Extent?
“High Cost of Hemophilia Therapy and Complex Treatment Procedures”
Market expansion is constrained by the high cost of hemophilia therapy. The market for rare hemophilia factors is expected to have slow growth due to many variables, including a higher risk of joint damage, an increased chance of spontaneous bleeding, and issues with blood clotting.
How Can Emerging Companies Penetrate This Market?
“Aspiring Market Players Should Invest in R&D to Introduce New Therapies”
Most people don't worry too much over a minor cut on their hand or foot. They can apply a Band-Aid and get on with their lives. However, those who have hemophilia may experience serious bleeding and other medical problems with even the smallest cut or bruise.
Hemophilia affects roughly one in every 5,000 male births and is brought on by a genetic mutation that affects the genes that allow for the production of clotting proteins. Although uncommon, it can also happen to women. Hemophilia also contributes to progressive joint degeneration or recurrent joint bleeding in many of these patients.
Because they are exclusively for people who don't have problems with their immune system after having a therapeutic infusion, the available gene therapies for hemophilia are now restricted. Additionally, the majority of therapies are made to help people with hemophilia A or B who do not have inhibitors, but none of them addresses both forms of the condition, whether they have inhibitors or not. New companies are heavily investing in R&D to introduce new therapies to the market.
- A start-up based in the U.S., GeneVentiv Therapeutics offers the first universal gene therapy for hemophilia, even in the most challenging instances. This firm is fostering new hope in hemophilia sufferers by aiming to bring innovative therapies to market as they struggle with the day-to-day effects of their fatal, genetic condition.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Which Region Provides Optimistic Opportunities for Market Players?
“Growing Preference of Prophylaxis Medical Care in North America”
North America dominates the global market. People living in the region are changing their attitudes toward prophylaxis medical care, and this is predicted to have a significant positive impact on market growth.
The strong presence of key players, growing initiatives to enhance rare hemophilia disorder therapies, and government attempts to increase diagnosis rates and lower treatment costs are some of the elements supporting market expansion.
Country-wise Insights
What’s Driving Rare Hemophilia Factor Demand in S. Korea?
“Rising Prevalence of Hemophilia in the Country”
The therapeutic advances in hemophilia, the rise in consumer awareness about technologically advanced products, the growing prevalence of hemophilia, and the existence of a large patient pool are the main factors propelling the growth of the market in Korea.
What is the Demand Outlook for Rare Hemophilia Factors in the U.S.?
“Reimbursement Policies Supported by U.S. Government”
Numerous research grants are available for the rare disease study from the National Organization for Rare Disorders (NORD), which has its main office in the United States. Additionally, new U.S. FDA approvals of certain coagulation factor concentrates have contributed to market growth.
Better healthcare infrastructure, reimbursement policies supported by the government, and significant innovations by leading market participants in the form of new product launches are driving market expansion in the U.S.
What are the Growth Opportunities for Rare Hemophilia Factors across Japan?
“Constant Advances in Genetic Research in Japan”
The market in Japan is estimated to develop at a CAGR of 5.7% over the forecast period. Rising autosomal recessive disorder incidence, elevated consumer awareness of the significance of bleeding disorders, and an increase in product approvals are all contributing to market expansion.
With constant advances in genetic research and supportive government efforts, the market is expected to rise quickly during the projection period.
Category-wise Insights
Why is Demand for Factor VII Gaining Ground?
“Wide Accessibility of Therapeutic Choices Driving Demand for Factor VII”
Based on type, rare hemophilia factors are divided into factor I, factor II, factor V, factor VII, factor X, factor XI, and factor XIII.
Due to initiatives conducted by organizations such as the World Federation of Hemophilia for patient advocacy and enhancing diagnosis and treatment of rare hemophilia diseases, awareness of rare hemophilia deficits is predicted to rise throughout the forecast period.
Factor VII is anticipated to hold a significant position in the global market. High factor VII demand might be ascribed to the accessibility of therapeutic choices such as NovoSeven, a recombinant form of factor VIIa.
Which Application is at the Forefront of Rare Hemophilia Factor Demand?
“Fresh Frozen Plasma Highly Used to Prevent Bleeding Before Urgent Invasive Operations”
Based on application, rare hemophilia factors are classified into fresh frozen plasma, factor concentrates, cryoprecipitate, and others.
Fresh frozen plasma accounts for 40% share of the global market. All blood proteins and coagulation factors are present in fresh frozen plasma.
Plasma transfusion is suggested to control bleeding or to prevent bleeding before an urgent surgical intervention in patients who require the replacement of multiple coagulation factors. The fluid component of a unit of whole blood, known as fresh frozen plasma, is frozen for a specific amount of time, often within 8 hours. The recipient's red cells must be ABO-compatible with the FFP. Market expansion is fueled by research & development in the field of fresh frozen plasma.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Competitive Landscape
Several key companies are embracing techniques, including strategic partnerships and marketing to boost the awareness of novel techniques.
For instance :
- In 2020, to prevent and treat bleeding in people with hemophilia A, Novo Nordisk announced the release of ESPEROCT, a long-acting recombinant factor VIII medication. This novel medicine is specifically recommended for routine prophylaxis to lessen the incidence of major bleeding, provide on-demand treatment, and manage bleeding during surgery.
Key Segments in Rare Hemophilia Factors Industry Research
-
By Type :
- Factor I
- Factor II
- Factor V
- Factor VII
- Factor X
- Factor XI
- Factor XIII
-
By Application :
- Fresh Frozen Plasma
- Factor Concentrates
- Cryoprecipitate
- Others
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions/Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Type modifications /Innovation 4. Key Success Factors 4.1. Strategic Developments 4.2. Key regulations 4.3. Type USPs /Technology 4.4. List of Manufacturers and Providers 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP outlook 5.1.2. Increasing R&D Expenditure 5.2. Forecast Factors - Relevance & Impact 5.2.1. New Type launches 5.2.2. Cost of Types 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID19 Crisis Analysis 6.1. Current COVID19 Statistics and Probable Future Impact 6.2. Current GDP Projection and Probable Impact 6.3. Current Economic Projection as Compared to 2008 Economic analysis 6.4. COVID19 and Impact Analysis 6.4.1. Revenue By Type 6.4.2. Revenue By Application 6.4.3. Revenue By Country 6.5. 2021 Market Scenario 6.6. Quarter by Quarter Forecast 6.7. Projected Recovery Quarter 7. Global Rare Hemophilia Factors Market Volume (Units) Analysis 2017-2021 and Forecast, 2022-2032 7.1. Historical Market Volume (Units) Analysis, 2017-2021 7.2. Current and Future Market Volume (Units) Projections, 2022-2032 7.2.1. Y-o-Y Growth Trend Analysis 8. Global Rare Hemophilia Factors Market - Pricing Analysis 8.1. Regional Pricing Analysis By Type 8.2. Pricing Break-up 8.2.1. Manufacturer Level Pricing 8.2.2. Distributor Level Pricing 8.3. Global Average Pricing Analysis Benchmark 9. Global Rare Hemophilia Factors Market Value Analysis 2017–2021 and Forecast, 2022-2032 9.1. Historical Market Value (US$ Mn) Analysis, 2017–2021 9.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032 9.2.1. Y-o-Y Growth Trend Analysis 9.2.2. Absolute $ Opportunity Analysis 10. Global Rare Hemophilia Factors Market Analysis 2017–2021 and Forecast 2022-2032, by Type 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Types & Services, 2017–2021 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Type, 2022-2032 10.3.1. Fresh Frozen Plasma 10.3.2. Factor Concentrates 10.3.3. Cryoprecipitate 10.3.4. Others 10.4. Market Attractiveness Analysis By Type 11. Global Rare Hemophilia Factors Market Analysis 2017–2021 and Forecast 2022-2032, by Application 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By Application , 2017–2021 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application , 2022-2032 11.3.1. Factor I 11.3.2. Factor II 11.3.3. Factor V 11.3.4. Factor VII 11.3.5. Factor X 11.3.6. Factor XI 11.3.7. Factor XIII 11.4. Market Attractiveness Analysis By Application 12. Global Rare Hemophilia Factors Market Analysis 2017–2021 and Forecast 2022-2032, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2017–2021 12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2032 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Rare Hemophilia Factors Market Analysis 2017–2021 and Forecast 2022-2032 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Type 13.3.3. By Application 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Latin America Rare Hemophilia Factors Market Analysis 2017–2021 and Forecast 2022-2032 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Type 14.3.3. By Application 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. Europe Rare Hemophilia Factors Market Analysis 2017–2021 and Forecast 2022-2032 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. Russia 15.3.1.7. Rest of Europe 15.3.2. By Type 15.3.3. By Application 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. South Asia Rare Hemophilia Factors Market Analysis 2017–2021 and Forecast 2022-2032 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Rest of South Asia 16.3.2. By Type 16.3.3. By Application 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. East Asia Rare Hemophilia Factors Market Analysis 2017–2021 and Forecast 2022-2032 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.1.4. Rest of East Asia 17.3.2. By Type 17.3.3. By Application 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Oceania Rare Hemophilia Factors Market Analysis 2017–2021 and Forecast 2022-2032 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Type 18.3.3. By Application 18.4. Market Attractiveness Analysis 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 19. Middle East and Africa Rare Hemophilia Factors Market Analysis 2017–2021 and Forecast 2022-2032 19.1. Introduction 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021 19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2032 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. South Africa 19.3.1.3. Rest of Middle East and Africa 19.3.2. By Type 19.3.3. By Application 19.4. Market Attractiveness Analysis 19.5. Drivers and Restraints - Impact Analysis 20. Key and Emerging Countries Rare Hemophilia Factors Market Analysis 2017–2021 and Forecast 2022-2032 20.1. Introduction 20.1.1. Market Value Proportion Analysis, By Key Countries 20.1.2. Global Vs. Country Growth Comparison 20.2. U.S. Rare Hemophilia Factors Market Analysis 20.2.1. By Type 20.2.2. By Application 20.3. Canada Rare Hemophilia Factors Market Analysis 20.3.1. By Type 20.3.2. By Application 20.4. Mexico Rare Hemophilia Factors Market Analysis 20.4.1. By Type 20.4.2. By Application 20.5. Brazil Rare Hemophilia Factors Market Analysis 20.5.1. By Type 20.5.2. By Application 20.6. U.K. Rare Hemophilia Factors Market Analysis 20.6.1. By Type 20.6.2. By Application 20.7. Germany Rare Hemophilia Factors Market Analysis 20.7.1. By Type 20.7.2. By Application 20.8. France Rare Hemophilia Factors Market Analysis 20.8.1. By Type 20.8.2. By Application 20.9. Italy Rare Hemophilia Factors Market Analysis 20.9.1. By Type 20.9.2. By Application 20.10. Spain Rare Hemophilia Factors Market Analysis 20.10.1. By Type 20.10.2. By Application 20.11. BENELUX Rare Hemophilia Factors Market Analysis 20.11.1. By Type 20.11.2. By Application 20.12. Russia Rare Hemophilia Factors Market Analysis 20.12.1. By Type 20.12.2. By Application 20.13. China Rare Hemophilia Factors Market Analysis 20.13.1. By Type 20.13.2. By Application 20.14. Japan Rare Hemophilia Factors Market Analysis 20.14.1. By Type 20.14.2. By Application 20.15. South Korea Rare Hemophilia Factors Market Analysis 20.15.1. By Type 20.15.2. By Application 20.16. India Rare Hemophilia Factors Market Analysis 20.16.1. By Type 20.16.2. By Application 20.17. ASEAN Rare Hemophilia Factors Market Analysis 20.17.1. By Type 20.17.2. By Application 20.18. Australia Rare Hemophilia Factors Market Analysis 20.18.1. By Type 20.18.2. By Application 20.19. New Zealand Rare Hemophilia Factors Market Analysis 20.19.1. By Type 20.19.2. By Application 20.20. GCC Countries Rare Hemophilia Factors Market Analysis 20.20.1. By Type 20.20.2. By Application 20.21. Turkey Rare Hemophilia Factors Market Analysis 20.21.1. By Type 20.21.2. By Application 20.22. South Africa Rare Hemophilia Factors Market Analysis 20.22.1. By Type 20.22.2. By Application 21. Market Structure Analysis 21.1. Market Analysis by Tier of Companies 21.2. Market Concentration 21.3. Market Share Analysis of Top Players 21.4. Market Presence Analysis 21.4.1. By Regional footprint of Players 21.4.2. Type foot print by Players 21.4.3. Channel Foot Print by Players 22. Competition Analysis 22.1. Competition Dashboard 22.2. Competition Benchmarking 22.3. Competition Deep dive 22.3.1. Amgen Inc. 22.3.1.1. Overview 22.3.1.2. Type Portfolio 22.3.1.3. Profitability by Market Segments (Type/Channel/Region) 22.3.1.4. Sales Footprint 22.3.1.5. Strategy Overview 22.3.2. BioMarin 22.3.2.1. Overview 22.3.2.2. Type Portfolio 22.3.2.3. Profitability by Market Segments (Type/Channel/Region) 22.3.2.4. Sales Footprint 22.3.2.5. Strategy Overview 22.3.3. Bio Products Laboratory Ltd. 22.3.3.1. Overview 22.3.3.2. Type Portfolio 22.3.3.3. Profitability by Market Segments (Type/Channel/Region) 22.3.3.4. Sales Footprint 22.3.3.5. Strategy Overview 22.3.4. Biogen Inc. 22.3.4.1. Overview 22.3.4.2. Type Portfolio 22.3.4.3. Profitability by Market Segments (Type/Channel/Region) 22.3.4.4. Sales Footprint 22.3.4.5. Strategy Overview 22.3.5. CSL Behring 22.3.5.1. Overview 22.3.5.2. Type Portfolio 22.3.5.3. Profitability by Market Segments (Type/Channel/Region) 22.3.5.4. Sales Footprint 22.3.5.5. Strategy Overview 22.3.6. Baxter International Inc. 22.3.6.1. Overview 22.3.6.2. Type Portfolio 22.3.6.3. Profitability by Market Segments (Type/Channel/Region) 22.3.6.4. Sales Footprint 22.3.6.5. Strategy Overview 22.3.7. Bayer AG 22.3.7.1. Overview 22.3.7.2. Type Portfolio 22.3.7.3. Profitability by Market Segments (Type/Channel/Region) 22.3.7.4. Sales Footprint 22.3.7.5. Strategy Overview 22.3.8. Novo Nordisk A/S 22.3.8.1. Overview 22.3.8.2. Type Portfolio 22.3.8.3. Profitability by Market Segments (Type/Channel/Region) 22.3.8.4. Sales Footprint 22.3.8.5. Strategy Overview 22.3.9. Pfizer, Inc. 22.3.9.1. Overview 22.3.9.2. Type Portfolio 22.3.9.3. Profitability by Market Segments (Type/Channel/Region) 22.3.9.4. Sales Footprint 22.3.9.5. Strategy Overview 22.3.10. Takeda Pharmaceutical Co. Ltd. 22.3.10.1. Overview 22.3.10.2. Type Portfolio 22.3.10.3. Profitability by Market Segments (Type/Channel/Region) 22.3.10.4. Sales Footprint 22.3.10.5. Strategy Overview 22.3.11. Alexion Pharmaceuticals, Inc. 22.3.11.1. Overview 22.3.11.2. Type Portfolio 22.3.11.3. Profitability by Market Segments (Type/Channel/Region) 22.3.11.4. Sales Footprint 22.3.11.5. Strategy Overview 22.3.12. Shire plc 22.3.12.1. Overview 22.3.12.2. Type Portfolio 22.3.12.3. Profitability by Market Segments (Type/Channel/Region) 22.3.12.4. Sales Footprint 22.3.12.5. Strategy Overview 22.3.13. ICON plc 22.3.13.1. Overview 22.3.13.2. Type Portfolio 22.3.13.3. Profitability by Market Segments (Type/Channel/Region) 22.3.13.4. Sales Footprint 22.3.13.5. Strategy Overview 23. Assumptions and Acronyms Used 24. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Rare Hemophilia Factors Market Volume (‘000 Units) Analysis and Opportunity Assessment 2017–2032, By Type
Table 02: Global Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Type
Table 03: Global Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Application
Table 04: Global Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Region
Table 05: North America Rare Hemophilia Factors Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022–2032, By Country
Table 06: North America Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Type
Table 07: North America Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Application
Table 08: Latin America Rare Hemophilia Factors Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022–2032, By Country
Table 09: Latin America Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Type
Table 10: Latin America Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Application
Table 11: Europe Rare Hemophilia Factors Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022–2032, By Country
Table 12: Europe Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Type
Table 13: Europe Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Application
Table 14: South Asia Rare Hemophilia Factors Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022–2032, By Country
Table 15: South Asia Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Type
Table 16: South Asia Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Application
Table 17: East Asia Rare Hemophilia Factors Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022–2032, By Country
Table 18: East Asia Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Type
Table 19: East Asia Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Application
Table 20: Oceania Rare Hemophilia Factors Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022–2032, By Country
Table 21: Oceania Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Type
Table 22: Oceania Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Application
Table 23: Middle East and Africa Rare Hemophilia Factors Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022–2032, By Country
Table 24: Middle East and Africa Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Type
Table 25: Middle East and Africa Rare Hemophilia Factors Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2032, By Application
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Rare Hemophilia Factors Market Volume (in 000' Units) Analysis, 2017-2021
Figure 02: Global Rare Hemophilia Factors Market Volume Forecast (in 000' Units), 2022-2032
Figure 03: Rare Hemophilia Factors Pricing Analysis (US$) Per Type, By Region, 2021
Figure 04: Rare Hemophilia Factors Pricing Analysis (US$) Per Type, By Region, 2021
Figure 05: Global Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2017-2021
Figure 06: Global Rare Hemophilia Factors Market Value Forecast (US$ Mn), 2022-2032
Figure 07: Global Rare Hemophilia Factors Market Absolute $ Opportunity, 2022-2032
Figure 08: Global Rare Hemophilia Factors Market Share Analysis (%), By Type, 2022-2032
Figure 09: Global Rare Hemophilia Factors Market Y-o-Y Analysis (%), By Type, 2022-2032
Figure 10: Global Rare Hemophilia Factors Market Attractiveness Analysis by Type, 2022-2032
Figure 11: Global Rare Hemophilia Factors Market Share Analysis (%), By Application, 2022-2032
Figure 12: Global Rare Hemophilia Factors Market Y-o-Y Analysis (%), By Application, 2022-2032
Figure 13: Global Rare Hemophilia Factors Market Attractiveness Analysis by Application, 2022-2032
Figure 14: Global Rare Hemophilia Factors Market Share Analysis (%), By Region, 2022-2032
Figure 15: Global Rare Hemophilia Factors Market Y-o-Y Analysis (%), By Region, 2022-2032
Figure 16: Global Rare Hemophilia Factors Market Attractiveness Analysis by Region, 2022-2032
Figure 17: North America Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 18: North America Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 19: North America Rare Hemophilia Factors Market Value Share, By Country, 2022 (E)
Figure 20: North America Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2017-2021
Figure 21: North America Rare Hemophilia Factors Market Value Forecast (US$ Mn), 2022-2032
Figure 22: North America Rare Hemophilia Factors Market Attractiveness Analysis by Type, 2022-2032
Figure 23: North America Rare Hemophilia Factors Market Attractiveness Analysis by Application, 2022-2032
Figure 24: North America Rare Hemophilia Factors Market Attractiveness Analysis by Country, 2022-2032
Figure 25: Latin America Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 26: Latin America Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 27: Latin America Rare Hemophilia Factors Market Value Share, By Country, 2022 (E)
Figure 28: Latin America Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2017-2021
Figure 29: Latin America Rare Hemophilia Factors Market Value Forecast (US$ Mn), 2022-2032
Figure 30: Latin America Rare Hemophilia Factors Market Attractiveness Analysis by Type, 2022-2032
Figure 31: Latin America Rare Hemophilia Factors Market Attractiveness Analysis by Application, 2022-2032
Figure 32: Latin America Rare Hemophilia Factors Market Attractiveness Analysis by Country, 2022-2032
Figure 33: Europe Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 34: Europe Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 35: Europe Rare Hemophilia Factors Market Value Share, By Country, 2022 (E)
Figure 36: Europe Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2017-2021
Figure 37: Europe Rare Hemophilia Factors Market Value Forecast (US$ Mn), 2022-2032
Figure 38: Europe Rare Hemophilia Factors Market Attractiveness Analysis by Type, 2022-2032
Figure 39: Europe Rare Hemophilia Factors Market Attractiveness Analysis by Application, 2022-2032
Figure 40: Europe Rare Hemophilia Factors Market Attractiveness Analysis by Country, 2022-2032
Figure 41: South Asia Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 42: South Asia Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 43: South Asia Rare Hemophilia Factors Market Value Share, By Country, 2022 (E)
Figure 44: South Asia Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2017-2021
Figure 45: South Asia Rare Hemophilia Factors Market Value Forecast (US$ Mn), 2022-2032
Figure 46: South Asia Rare Hemophilia Factors Market Attractiveness Analysis by Type, 2022-2032
Figure 47: South Asia Rare Hemophilia Factors Market Attractiveness Analysis by Application, 2022-2032
Figure 48: South Asia Rare Hemophilia Factors Market Attractiveness Analysis by Country, 2022-2032
Figure 49: East Asia Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 50: East Asia Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 51: East Asia Rare Hemophilia Factors Market Value Share, By Country, 2022 (E)
Figure 52: East Asia Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2017-2021
Figure 53: East Asia Rare Hemophilia Factors Market Value Forecast (US$ Mn), 2022-2032
Figure 54: East Asia Rare Hemophilia Factors Market Attractiveness Analysis by Type, 2022-2032
Figure 55: East Asia Rare Hemophilia Factors Market Attractiveness Analysis by Application, 2022-2032
Figure 56: East Asia Rare Hemophilia Factors Market Attractiveness Analysis by Country, 2022-2032
Figure 57: Oceania Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 58: Oceania Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 59: Oceania Rare Hemophilia Factors Market Value Share, By Country, 2022 (E)
Figure 60: Oceania Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2017-2021
Figure 61: Oceania Rare Hemophilia Factors Market Value Forecast (US$ Mn), 2022-2032
Figure 62: Oceania Rare Hemophilia Factors Market Attractiveness Analysis by Type, 2022-2032
Figure 63: Oceania Rare Hemophilia Factors Market Attractiveness Analysis by Application, 2022-2032
Figure 64: Oceania Rare Hemophilia Factors Market Attractiveness Analysis by Country, 2022-2032
Figure 65: Middle East and Africa Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 66: Middle East and Africa Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 67: Middle East and Africa Rare Hemophilia Factors Market Value Share, By Country, 2022 (E)
Figure 68: Middle East and Africa Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2017-2021
Figure 69: Middle East and Africa Rare Hemophilia Factors Market Value Forecast (US$ Mn), 2022-2032
Figure 70: Middle East and Africa Rare Hemophilia Factors Market Attractiveness Analysis by Type, 2022-2032
Figure 71: Middle East and Africa Rare Hemophilia Factors Market Attractiveness Analysis by Application, 2022-2032
Figure 72: Middle East and Africa Rare Hemophilia Factors Market Attractiveness Analysis by Country, 2022-2032
Figure 73: U. S. Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 74: U. S. Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 75: U. S. Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 76: Canada Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 77: Canada Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 78: Canada Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 79: Mexico Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 80: Mexico Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 81: Mexico Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 82: Brazil Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 83: Brazil Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 84: Brazil Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 85: U. K. Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 86: U. K. Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 87: U. K. Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 88: Germany Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 89: Germany Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 90: Germany Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 91: France Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 92: France Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 93: France Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 94: Italy Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 95: Italy Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 96: Italy Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 97: Spain Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 98: Spain Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 99: Spain Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 100: Russia Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 101: Russia Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 102: Russia Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 103: China Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 104: China Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 105: China Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 106: Japan Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 107: Japan Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 108: Japan Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 109: South Korea Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 110: South Korea Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 111: South Korea Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 112: India Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 113: India Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 114: India Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 115: ASEAN Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 116: ASEAN Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 117: ASEAN Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 118: Australia Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 119: Australia Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 120: Australia Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 121: New Zealand Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 122: New Zealand Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 123: New Zealand Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 124: GCC Countries Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 125: GCC Countries Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 126: GCC Countries Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 127: Turkey Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 128: Turkey Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 129: Turkey Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Figure 130: South Africa Rare Hemophilia Factors Market Value Analysis (US$ Mn), 2022 & 2032
Figure 131: South Africa Rare Hemophilia Factors Market Value Share, By Type, 2022 (E)
Figure 132: South Africa Rare Hemophilia Factors Market Value Share, By Application, 2022 (E)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the rare hemophilia factors market predicted growth?
The global rare hemophilia factors market is projected to progress at 6% CAGR and reach US$ 520 million by 2032.
What are the key factors driving market growth?
Rising adoption & approval of new treatment techniques and growing number of government initiatives & funding are driving market growth.
Who are the key players in the rare hemophilia factors market?
Amgen Inc., BioMarin, and Bio Products Laboratory Ltd. are the key players in this market.
What is the rare hemophilia factors market size?
Currently, the global market for rare hemophilia factors is valued at US$ 290 million.
What is the estimated CAGR for the market in Germany?
The rare hemophilia factors market in Germany is expected to increase at 5.8% CAGR through 2032.
Rare Hemophilia Factors Market